CHARACTERISTICS OF FIRST-LINE UPADACITINIB INITIATORS AND FACTORS CONTRIBUTING TO PRESCRIBING UPADACITINIB AS FIRST-LINE B/ TSDMARD

被引：0

|

作者：

Krueger, W. ^{[1
]}

Harrold, L. ^{[2
]}

Sima, A. ^{[3
]}

Eckmann, T. ^{[3
]}

Kilpatrick, R. ^{[1
]}

机构：

[1] AbbVie Inc, Chicago, IL USA

[2] Univ Massachusetts, Sch Med, Worcester, MA USA

[3] CorEvitas, Waltham, MA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Disease-modifying Drugs (DMARDs); Real-world evidence; Rheumatoid arthritis;

D O I：

10.1136/annrheumdis-2023-eular.3284

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

AB0445

引用

收藏

页码：1412 / 1412

页数：1

相关论文

共 50 条

[41] New first-line options in CLL
Romero, Diana
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (09) : 526 - 527
[42] First-line approach to thoracic trauma
Lubberink, AAME
TIJDSCHRIFT VOOR DIERGENEESKUNDE, 1997, 122 (24) : 705 - 707
[43] Novel promising first-line combination
不详
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (03) : 134 - 134
[44] Benefit with first-line ICIs in mesothelioma
Romero, Diana
NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (04) : 194 - 194
[45] DOCTORS, NURSES AND FIRST-LINE CARE
FLOOK, N
CANADIAN FAMILY PHYSICIAN, 1995, 41 : 1455 - 1458
[46] Rituximab as first-line treatment of pemphigus
Schmidt, Enno
LANCET, 2017, 389 (10083): : 1956 - 1958
[47] First-Line Therapy for Immune Thrombocytopenia
Mithoowani, Siraj
Arnold, Donald M.
HAMOSTASEOLOGIE, 2019, 39 (03): : 258 - 265
[48] 2009: the year of first-line maintenance?
Perol, M.
REVUE DE PNEUMOLOGIE CLINIQUE, 2009, 65 : S75 - S79
[49] AIH Therapy: Beyond First-Line
Adao I.
Klepper A.
Tana M.
Current Hepatology Reports, 2024, 23 (3) : 341 - 348
[50] A confirmed first-line option for CLL
Rebecca Kirk
Nature Reviews Clinical Oncology, 2011, 8 (5) : 253 - 253

← 1 2 3 4 5 →